Cell targeting by murine recombinant retroviruses. 1992

M Etienne-Julan, and P Roux, and P Bourquard, and S Carillo, and P Jeanteur, and M Piechaczyk
Laboratoire de Biologie Moléculaire, URA CNRS 1191, Génétique Moléculaire, USTL, Montpellier, France.

Cell targeting by murine retroviruses carrying recombinant genes would have numerous applications such as immortalization of under-represented cell types from complex cellular mixtures, increasing therapeutical yields in the case of gene therapy and delivery of specific genes at any location and at any moment of the life-time of living animals. To this aim, we are currently developing techniques that allow binding of viral particles to specific cell membrane markers different from the natural receptors. We have shown that biochemical bi-specific molecular adaptors able to bind both viral particles and cell surface molecules may reveal appropriate for piloting viruses toward specific cell types. More recently, we have undertaken the genetic engineering of the retroviral envelope glycoprotein in order to modify its natural tropism. This approach is discussed below.

UI MeSH Term Description Entries
D008979 Moloney murine leukemia virus A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) arising during the propagation of S37 mouse sarcoma, and causing lymphoid leukemia in mice. It also infects rats and newborn hamsters. It is apparently transmitted to embryos in utero and to newborns through mother's milk. Moloney Leukemia Virus,Leukemia Virus, Moloney,Virus, Moloney Leukemia
D011991 Receptors, Virus Specific molecular components of the cell capable of recognizing and interacting with a virus, and which, after binding it, are capable of generating some signal that initiates the chain of events leading to the biological response. Viral Entry Receptor,Viral Entry Receptors,Virus Attachment Factor,Virus Attachment Factors,Virus Attachment Receptor,Virus Attachment Receptors,Virus Entry Receptor,Virus Entry Receptors,Virus Receptor,Virus Receptors,Attachment Factor, Virus,Attachment Factors, Virus,Attachment Receptor, Virus,Attachment Receptors, Virus,Entry Receptor, Viral,Entry Receptor, Virus,Entry Receptors, Viral,Entry Receptors, Virus,Receptor, Viral Entry,Receptor, Virus,Receptor, Virus Attachment,Receptor, Virus Entry,Receptors, Viral Entry,Receptors, Virus Attachment,Receptors, Virus Entry
D003673 Defective Viruses Viruses which lack a complete genome so that they cannot completely replicate or cannot form a protein coat. Some are host-dependent defectives, meaning they can replicate only in cell systems which provide the particular genetic function which they lack. Others, called SATELLITE VIRUSES, are able to replicate only when their genetic defect is complemented by a helper virus. Incomplete Viruses,Defective Hybrids,Defective Hybrid,Defective Virus,Hybrid, Defective,Hybrids, Defective,Incomplete Virus,Virus, Defective,Virus, Incomplete,Viruses, Defective,Viruses, Incomplete
D005818 Genetic Engineering Directed modification of the gene complement of a living organism by such techniques as altering the DNA, substituting genetic material by means of a virus, transplanting whole nuclei, transplanting cell hybrids, etc. Genetic Intervention,Engineering, Genetic,Intervention, Genetic,Genetic Interventions,Interventions, Genetic
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014162 Transfection The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES. Transfections
D014759 Viral Envelope Proteins Integral membrane proteins that are incorporated into the VIRAL ENVELOPE. They are glycosylated during VIRAL ASSEMBLY. Envelope Proteins, Viral,Viral Envelope Glycoproteins,Viral Envelope Protein,Virus Envelope Protein,Virus Peplomer Proteins,Bovine Leukemia Virus Glycoprotein gp51,Hepatitis Virus (MHV) Glycoprotein E2,LaCrosse Virus Envelope Glycoprotein G1,Simian Sarcoma Virus Glycoprotein 70,Viral Envelope Glycoprotein gPr90 (Murine Leukemia Virus),Viral Envelope Glycoprotein gp55 (Friend Virus),Viral Envelope Proteins E1,Viral Envelope Proteins E2,Viral Envelope Proteins gp52,Viral Envelope Proteins gp70,Virus Envelope Proteins,Envelope Glycoproteins, Viral,Envelope Protein, Viral,Envelope Protein, Virus,Envelope Proteins, Virus,Glycoproteins, Viral Envelope,Peplomer Proteins, Virus,Protein, Viral Envelope,Protein, Virus Envelope,Proteins, Viral Envelope,Proteins, Virus Envelope,Proteins, Virus Peplomer
D015682 Retroviridae Proteins, Oncogenic Retroviral proteins that have the ability to transform cells. They can induce sarcomas, leukemias, lymphomas, and mammary carcinomas. Not all retroviral proteins are oncogenic. Oncogenic Retroviridae Proteins,Proteins, Oncogenic Retroviridae

Related Publications

M Etienne-Julan, and P Roux, and P Bourquard, and S Carillo, and P Jeanteur, and M Piechaczyk
September 1997, Molecular medicine today,
M Etienne-Julan, and P Roux, and P Bourquard, and S Carillo, and P Jeanteur, and M Piechaczyk
June 1998, Critical reviews in oncology/hematology,
M Etienne-Julan, and P Roux, and P Bourquard, and S Carillo, and P Jeanteur, and M Piechaczyk
November 2008, Cellular and molecular life sciences : CMLS,
M Etienne-Julan, and P Roux, and P Bourquard, and S Carillo, and P Jeanteur, and M Piechaczyk
December 2015, Cellular and molecular life sciences : CMLS,
M Etienne-Julan, and P Roux, and P Bourquard, and S Carillo, and P Jeanteur, and M Piechaczyk
June 1989, The EMBO journal,
M Etienne-Julan, and P Roux, and P Bourquard, and S Carillo, and P Jeanteur, and M Piechaczyk
January 1985, Nature,
M Etienne-Julan, and P Roux, and P Bourquard, and S Carillo, and P Jeanteur, and M Piechaczyk
January 2001, Methods in molecular medicine,
M Etienne-Julan, and P Roux, and P Bourquard, and S Carillo, and P Jeanteur, and M Piechaczyk
December 1988, Journal of virology,
M Etienne-Julan, and P Roux, and P Bourquard, and S Carillo, and P Jeanteur, and M Piechaczyk
October 1992, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
M Etienne-Julan, and P Roux, and P Bourquard, and S Carillo, and P Jeanteur, and M Piechaczyk
June 1984, Clinics in haematology,
Copied contents to your clipboard!